AMLX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AMLX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Amylyx Pharmaceuticals's net interest income for the three months ended in Dec. 2023 was $4.4 Mil. Its net interest income for the trailing twelve months (TTM) ended in Dec. 2023 was $16.2 Mil.
The historical data trend for Amylyx Pharmaceuticals's Net Interest Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amylyx Pharmaceuticals Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Net Interest Income | -1.10 | -2.27 | 0.04 | 4.29 | 16.16 |
Amylyx Pharmaceuticals Quarterly Data | |||||||||||||||
Dec19 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Net Interest Income | Get a 7-Day Free Trial | 3.16 | 3.72 | 3.89 | 4.18 | 4.37 |
Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.
Net Interest Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $16.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Amylyx Pharmaceuticals's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Joshua B Cohen | director, officer: Co-Chief Executive Officer | C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141 |
Justin B. Klee | director, officer: Co-Chief Executive Officer | C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141 |
Patrick D Yeramian | officer: Chief Medical Officer | 1815 PARKSIDE CIRCLE SOUTH, BOCA RATON FL 33486 |
James M Frates | officer: Chief Financial Officer | 88 SIDNEY ST, CAMBRIDGE MA 021394136 |
Karen Firestone | director | C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE ST., CAMBRIDGE MA 02141 |
Gina Mazzariello | officer: Chief Legal Officer | C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141 |
Morningside Venture Investments Ltd | 10 percent owner | MCCARTHY LEGAL SERVICES, 1188 CENTRE STREET, NEWTON CENTRE MA 02459 |
Milne George M Jr | director | |
Margaret Olinger | officer: Chief Commercial Officer | C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141 |
Viking Global Investors Lp | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Dragsa 96 Llc | 10 percent owner | 55 RAILROAD AVE., GREENWICH CT 06830 |
Als Invest 1 B.v. | 10 percent owner | EERSTE WELERINGDWARSSTRAAL 54E, 1017 TP, AMSTERDAM P7 1017 |
Isaac Cheng | director | C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110 |
Mvil, Llc | 10 percent owner | 22ND FLOOR HANG LUNG CENTRE, 2-20 PATERSON STREET, CAUSEWAY BAY K3 00000 |
Ole Andreas Halvorsen | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
From GuruFocus
By PRNewswire • 12-10-2023
By PRNewswire • 11-29-2023
By Business Wire • 10-13-2023
By Business Wire • 12-22-2023
By Business Wire • 10-02-2023
By Business Wire • 09-05-2023
By Business Wire • 11-16-2023
By Business Wire • 11-29-2023
By Business Wire • 11-02-2023
By Business Wire • 10-10-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.